All In Biotech

Drug Trial Radar · NCT01072968

BF2.649 in Patients With OSA, Still Complaining of EDS and Refusing to be Treated by CPAP.

Efficacy and Safety of BF2.649 in Treatment of Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea (OSA) Refusing the Nasal Continuous Positive Airway Pressure (nCPAP) Therapy

Last checked: Nov 19, 2026Latest source record: Jan 21, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 268 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

268

Actual

Start

Oct 2011

Primary completion

May 2014

Study completion May 2014

Sponsor

Lead sponsor
BioprojetAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Feb 22, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Multicenter randomized double blind study versus placebo during 12 weeks with at first, an escalating dose period followed by stable dose period at the selected dose. This double-blind period can be followed by a 9 months open-label period if the patient wishes to continue with the study product.

Conditions

  • Obstructive Sleep Apnea
  • Excessive Daytime Sleepiness

Interventions

  • BF2.649Drug

    1 capsule per day in the morning before the breakfast

  • PlaceboDrug

    1 capsule per day in the morning before the breakfast

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. ESS (Epworth Sleepiness Scale) change from baselineTime frame: From baseline to week 12 and week 51

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Centre Hospitalier Universitaire de Grenoble

    Grenoble, Grenoble, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.